US 12,030,953 B2
Chimeric antigen receptors, compositions, and methods
Dan Samuel Kaufman, Woodbury, MN (US); David Lee Lampi Hermanson, San Diego, CA (US); and Branden Scott Moriarity, Shoreview, MN (US)
Assigned to Regents of the University of Minnesota, Minneapolis, MN (US)
Filed by REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Filed on Apr. 1, 2020, as Appl. No. 16/837,661.
Application 16/837,661 is a continuation of application No. 15/546,177, granted, now 10,640,570, previously published as PCT/US2016/015351, filed on Jan. 28, 2016.
Claims priority of provisional application 62/109,281, filed on Jan. 29, 2015.
Prior Publication US 2020/0291125 A1, Sep. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 35/17 (2013.01); C07K 14/4747 (2013.01); C07K 14/54 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); A61K 2039/505 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01)] 11 Claims
 
1. An isolated induced pluripotent stem cell comprising a polynucleotide encoding a chimeric antigen receptor molecule comprising, in an N-terminus to C-terminus orientation: an ectodomain comprising an antigen recognition region; a hinge; a transmembrane domain comprising a transmembrane region of NKG2D (cluster of differentiation 314 or CD314) in reverse orientation as compared to native NKG2D that natively has an extracellular C-terminus; and an endodomain comprising a functional signaling domain that activates a Natural Killer (NK) cell differentiated from the induced pluripotent stem cell wherein the functional signaling domain comprises an intracellular domain (ICD) from:
(a) 2B4 (cluster of differentiation 244 or CD244);
(b) 41BB (cluster of differentiation 137 or CD137);
(c) DAP12 (DNAX activation protein of 12 kDa) or DAP10;
(d) 2B4 and 41BB; or
(e) IL21R;
and further wherein the functional signaling domain comprises a signaling domain from CD3 zeta (CD3ζ).